Mizuho Securities Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Announces Target Price $48
Acadia Healthcare Is Maintained at Overweight by Barclays
Barclays Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Cuts Target Price to $43
Barclays Reaffirms Their Buy Rating on Acadia Healthcare (ACHC)
Deutsche Bank Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Maintains Target Price $45
RBC Capital Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Announces Target Price $64
Acadia Healthcare Is Maintained at Outperform by RBC Capital
Acadia Healthcare Co Analyst Ratings
RBC Cuts Price Target on Acadia Healthcare to $64 From $94, Keeps Outperform Rating
RBC Capital Reaffirms Their Buy Rating on Acadia Healthcare (ACHC)
TD Cowen Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Cuts Target Price to $70
Deutsche Bank Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Cuts Target Price to $45
BofA Securities Initiates Acadia Healthcare(ACHC.US) With Buy Rating, Announces Target Price $72
TD Cowen Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Maintains Target Price $91
Cantor Fitzgerald Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Maintains Target Price $90
Barclays Maintains Acadia Healthcare(ACHC.US) With Buy Rating, Maintains Target Price $76
Leerink Partners Maintains Acadia Healthcare(ACHC.US) With Buy Rating
Mizuho Securities Maintains Acadia Healthcare(ACHC.US) With Hold Rating, Cuts Target Price to $62
Acadia Healthcare Co Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)